Xiao Jin, Qing Xie, Xiangxiang Ding, Boqi Yu, Yan Zhang, Xiaofan Su, Chunhui Yuan, Ming Lu, Zhi Yang, Jiangyuan Yu
{"title":"Head-to-head comparison of [<sup>18</sup>F]AlF-NOTA-JR11 PET/MR and [<sup>68</sup>Ga]Ga-DOTA-TATE PET/CT in patients with neuroendocrine tumors.","authors":"Xiao Jin, Qing Xie, Xiangxiang Ding, Boqi Yu, Yan Zhang, Xiaofan Su, Chunhui Yuan, Ming Lu, Zhi Yang, Jiangyuan Yu","doi":"10.1007/s00259-026-08176-8","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To compare [<sup>18</sup>F] AlF-NOTA-JR11 PET/MR and [<sup>68</sup>Ga]Ga-DOTA-TATE PET/CT in patients with neuroendocrine tumors (NETs).</p><p><strong>Methods: </strong>Forty-one patients with biopsy-proven NETs were enrolled and underwent [<sup>68</sup>Ga]Ga-DOTA-TATE PET/CT and [<sup>18</sup>F] AlF-NOTA-JR11 PET/MR. Physiological organ uptake, lesion number, maximum standardized uptake value (SUV<sub>max</sub>) and tumor-to-background ratio (TBR) were compared between the two examinations.</p><p><strong>Results: </strong>[<sup>18</sup>F] AlF-NOTA-JR11 PET/MR and [<sup>68</sup>Ga]Ga-DOTA-TATE PET/CT depicted 924 and 580 lesions, respectively (p < 0.001).These included 754 and 405 liver metastases(p < 0.001), as well as 29 and 25 primary tumors (p = 0.125), respectively. The 405 liver metastases detected by both examinations were significantly larger than the 349 lesions detected only by [<sup>18</sup>F]AlF-NOTA-JR11 [median diameter, 14.00 mm (Q1, Q3: 10.00, 21,00) vs. 6.00 mm (Q1, Q3: 5.00, 9.00); p < 0.001]. No significant differences were found for the detection of lymph node metastases (p = 1.000) or bone metastases (p = 0.188). In the patient-based comparison, 76% of patients (31/41) had more lesions detected by [<sup>18</sup>F]AlF-NOTA-JR11 PET/MR than by [<sup>68</sup>Ga]Ga-DOTA-TATE PET/CT. Lesion SUV<sub>max</sub> for [<sup>18</sup>F]AlF-NOTA-JR11 was significantly lower than that for [<sup>68</sup>Ga]Ga-DOTA-TATE in primary tumors (p = 0.002), liver metastases (p = 0.017) and bone metastases (p = 0.008), whereas no significant difference was observed in lymph node metastases (p = 0.144). [<sup>18</sup>F]AlF-NOTA-JR11 PET/MR showed higher TBR than [<sup>68</sup>Ga]Ga-DOTA-TATE PET/CT in primary tumors (p = 0.014), lymph node metastases (p = 0.034) and liver metastases (p < 0.001), with no significant difference in bone metastases(p = 0.343).</p><p><strong>Conclusion: </strong>[<sup>18</sup>F]AlF-NOTA-JR11 PET/MR shows lower background uptake and higher TBR for primary tumors, lymph node metastases and liver metastases. It also detected more liver metastases than [<sup>68</sup>Ga]Ga-DOTA-TATE PET/CT. These findings provide valuable evidence supporting the clinical use of [<sup>18</sup>F]AlF-NOTA-JR11 PET/MR in patients with NETs.</p><p><strong>Trial registration number: </strong>2020KT15 DATE OF REGISTRATION: 30/03/2020.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":""},"PeriodicalIF":7.6000,"publicationDate":"2026-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Nuclear Medicine and Molecular Imaging","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00259-026-08176-8","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: To compare [18F] AlF-NOTA-JR11 PET/MR and [68Ga]Ga-DOTA-TATE PET/CT in patients with neuroendocrine tumors (NETs).
Methods: Forty-one patients with biopsy-proven NETs were enrolled and underwent [68Ga]Ga-DOTA-TATE PET/CT and [18F] AlF-NOTA-JR11 PET/MR. Physiological organ uptake, lesion number, maximum standardized uptake value (SUVmax) and tumor-to-background ratio (TBR) were compared between the two examinations.
Results: [18F] AlF-NOTA-JR11 PET/MR and [68Ga]Ga-DOTA-TATE PET/CT depicted 924 and 580 lesions, respectively (p < 0.001).These included 754 and 405 liver metastases(p < 0.001), as well as 29 and 25 primary tumors (p = 0.125), respectively. The 405 liver metastases detected by both examinations were significantly larger than the 349 lesions detected only by [18F]AlF-NOTA-JR11 [median diameter, 14.00 mm (Q1, Q3: 10.00, 21,00) vs. 6.00 mm (Q1, Q3: 5.00, 9.00); p < 0.001]. No significant differences were found for the detection of lymph node metastases (p = 1.000) or bone metastases (p = 0.188). In the patient-based comparison, 76% of patients (31/41) had more lesions detected by [18F]AlF-NOTA-JR11 PET/MR than by [68Ga]Ga-DOTA-TATE PET/CT. Lesion SUVmax for [18F]AlF-NOTA-JR11 was significantly lower than that for [68Ga]Ga-DOTA-TATE in primary tumors (p = 0.002), liver metastases (p = 0.017) and bone metastases (p = 0.008), whereas no significant difference was observed in lymph node metastases (p = 0.144). [18F]AlF-NOTA-JR11 PET/MR showed higher TBR than [68Ga]Ga-DOTA-TATE PET/CT in primary tumors (p = 0.014), lymph node metastases (p = 0.034) and liver metastases (p < 0.001), with no significant difference in bone metastases(p = 0.343).
Conclusion: [18F]AlF-NOTA-JR11 PET/MR shows lower background uptake and higher TBR for primary tumors, lymph node metastases and liver metastases. It also detected more liver metastases than [68Ga]Ga-DOTA-TATE PET/CT. These findings provide valuable evidence supporting the clinical use of [18F]AlF-NOTA-JR11 PET/MR in patients with NETs.
Trial registration number: 2020KT15 DATE OF REGISTRATION: 30/03/2020.
期刊介绍：
The European Journal of Nuclear Medicine and Molecular Imaging serves as a platform for the exchange of clinical and scientific information within nuclear medicine and related professions. It welcomes international submissions from professionals involved in the functional, metabolic, and molecular investigation of diseases. The journal's coverage spans physics, dosimetry, radiation biology, radiochemistry, and pharmacy, providing high-quality peer review by experts in the field. Known for highly cited and downloaded articles, it ensures global visibility for research work and is part of the EJNMMI journal family.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
